030-00234

VOID SHEET

New 7 = 96
122358

TO: License Fee Management Branch

FROM: RI

SUBJECT: VOIDED APPLICATION

Control Number: 122358

Applicant: ~~The~~ Medical Center of Central Massachusetts

Date Voided: 11-18-95

Reason for Void: Licensee withdrew their Amendment request in October 17th letter. After review. 20-02452-03

Rebecca J. Brown 11/18/95
Signature Date

Attachment:
Official Record Copy of
Voided Action

FOR LFMB USE ONLY

Final Review of VOID Completed:

Refund Authorized and processed

~~No~~ Refund Due

Fee Exempt or Fee Not Required

Comments: Aft rev in

Log completed

Processed by: BR

160009

OFFICIAL RECORD COPY ML 10

D/1

THE
MEDICAL
CENTER OF
CENTRAL
MASSACHUSETTS

281 Lincoln Street
Worcester, MA
01605-2152

(508) 792-8000
FAX (508) 792-8019

October 17, 1995

U. S. Nuclear Regulatory Commission, Region One
475 Allendale Road
King of Prussia, PA 19406-1915

Attn: Joanne Stambauth

Dear Ms. Stambauth:

The following is in regards to the letters sent to the NRC dated September 29, 1995 and October 4, 1995. I would like to provide you with some clarification of the current status of the following License Numbers:

20-02452-01
20-02452-03.

In doing so I would like to withdraw the above mentioned letters. Also, at this time I would like to bring to your attention that MCCM-Hahnemann and MCCM-Memorial are sister organizations currently operating under the corporate name of The Medical Center of Central Massachusetts, Inc.

As of October 1, 1995 the control of the Nuclear Medicine Department - Memorial was passed from the Department of Medicine to the Department of Radiology. These changes occurred fairly rapidly and unfortunately for a short period of time there was some breakdown in communication with those involved in the administration of the Department of Nuclear Medicine. Since that time the lines of communication have been clarified.

At present, those persons who are no longer associated with the Department of Nuclear Medicine at Memorial, and who are currently listed as authorized users on License Number 20-02452-01 are Peter Schneider, M.D. and James Hoogasian. All other authorized users listed on License Numbers 20-02452-01 and 20-02452-03 remain on the staff of The Medical Center of Central Massachusetts, and will remain on those licenses as authorized users. This includes Norio Higano, M. D., currently listed as the Radiation Safety Officer and who, for the present time, will remain as RSO.

In addition, the authorized users currently listed on the Hahnemann License Number 20-15761-01 will also be covering the Nuclear Medicine Department at Memorial. They will be doing so only in the capacity for which they are currently licensed under NRC License Number 20-15761-01.

I am currently working with F. X. Masse Associates, Health and Physics consultants to see what changes, if any, are needed in the current licenses. I have included copies of all licenses involved.

Hopefully, I have helped to clarify the situation here at MCCM. If you have any further questions please contact me at 508-793-6284.

Sincerely,

Daniel J. Jenkins, Supervisor
Department of Nuclear Medicine
The Med Center of Central Massachusetts

NRC FORM 374
(12-89)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 14

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10 Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. The Medical Center of Central Massachusetts
   Hahnemann Hospital Division
2. 281 Lincoln Street
   Worcester, Massachusetts 01605

In accordance with application dated September 28, 1990,

3. License number 20-15761-01 is amended in its entirety to read as follows:

4. Expiration date May 31, 1997

5. Docket or Reference No 030-09736

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material included in 10 CFR 35.100	A. Any radiopharmaceutical included in 10 CFR 35.100	A. As needed
B. Any byproduct material included in 10 CFR 35.200	B. Any radiopharmaceutical included in 10 CFR 35.200 except gas	B. As needed
C. Any byproduct material included in 10 CFR 35.300	C. Any radiopharmaceutical included in 10 CFR 35.300	C. As needed

9. Authorized use

A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
B. Any imaging and localization procedure approved in 10 CFR 35.200.
C. Diagnosis and treatment of hyperthyroidism, and treatment of cardiac dysfunction.

CONDITIONS

10. Location of use: 281 Lincoln Street, Worcester, Massachusetts.

11. Radiation Safety Officer: Richard O. Danford, M.D.

12.

Authorized Users:	Material and Users:
Richard O. Danford, M.D.	35.100; 35.200
James F. Lingley, M.D.	35.100; 35.200
David S. Schwartz, M.D.	35.100; 35.200
Paul Lock, M.D.	Iodine 131 as iodide for thyroid uptake studies, treatment of hyperthyroidism and cardiac dysfunction

NRC Form 374A (10-88) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

PAGE 2 OF 2 PAGES

License number: 20-15761-01

Docket or Reference number: 030-09736

Amendment No. 14

(12. Continued)

CONDITIONS

Authorized Users:	Material and Users:
R. Jacobs, M.D.	35.100; 35.200
Jacqueline Wellman, M.D.	35.100; 35.200
Richard A. Haas, M.D.	Iodine 131 as iodide for thyroid uptake studies, treatment of hyperthyroidism and cardiac dysfunction
Ronald J. Bick, M.D.	35.100; 35.200; 35.300 for treatment of hyperthyroidism and cardiac dysfunction
Edward F. Hurwitz, M.D.	35.100; 35.200; 35.300 for treatment of hyperthyroidism and cardiac dysfunction
George R. Edmonson, M.D.	35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material so that at no time is a quantity of radioactive material possessed in excess of a quantity which requires decommissioning funding in accordance with 10 CFR 30.35(d), 10 CFR 40.36(b), or 10 CFR 70.25(d).

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 28, 1990
B. Letter dated March 17, 1992

For the U.S. Nuclear Regulatory Commission

Date MAY 27 1992

By Original Signed By:
Michelle Beardsley
Nuclear Materials Safety Branch
Region I

NRC FORM 374
(10-88)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 39

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. The Medical Center of Central Massachusetts - Memorial 2. 119 Belmont Street Worcester, Massachusetts 01605-2982	In accordance with the letter dated March 3, 1994, 3. License number 20-02452-01 is amended in its entirety to read as follows: 4. Expiration date December 31, 1996 5. Docket or Reference No. 030-01847

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material included in 10 CFR 35.100	A. Any radiopharmaceutical included in 10 CFR 35.100	A. As needed
B. Any byproduct material included in 10 CFR 35.200	B. Any radiopharmaceutical included in 10 CFR 35.200	B. As needed
C. Any byproduct material included in 10 CFR 35.300	C. Any radiopharmaceutical included in 10 CFR 35.300	C. As needed
D. Any byproduct material included in 10 CFR 35.400	D. Any radiopharmaceutical included in 10 CFR 35.400	D. 2000 millicuries
E. Any byproduct material included in 10 CFR 35.500	E. Any diagnostic source included in 10 CFR 35.500	E. As needed
F. Any byproduct material included in 10 CFR 31.11	F. Prepackaged Kits	F. As needed
G. Hydrogen 3	G. Any	G. 100 millicuries
H. Carbon 14	H. Any	H. 50 millicuries
I. Phosphorus 32	I. Any	I. 40 millicuries
J. Chromium 51	J. Any	J. 10 millicuries
K. Iron 59	K. Any	K. 10 millicuries
L. Cobalt 58	L. Any	L. 10 millicuries
M. Cobalt 60	M. Any	M. 0.4 millicurie
N. Selenium 75	N. Any	N. 10 millicuries
O. Strontium 85	O. Any	O. 10 millicuries
P. Yttrium 90	P. Any	P. 400 millicuries
Q. Technetium 99m	Q. Any	Q. 100 millicuries
R. Indium 113m	R. Any	R. 100 millicuries
S. Iodine 125	S. Any	S. 15 millicuries
T. Iodine 131	T. Any	T. 15 millicuries
U. Ytterbium 169	U. Any	U. 10 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02452-01
Docket or Reference number: 030-01847
Amendment No. 39

(Items 6., 7., & 8. continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
V. Gold 198	V. Any	V. 10 millicuries
W. Mercury 197	W. Any	W. 10 millicuries
X. Mercury 203	X. Any	X. 10 millicuries
Y. Cesium 137	Y. Sealed sources	Y. 200 millicuries

9. Authorized use

A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
B. Any imaging and localization procedure approved in 10 CFR 35.200.
C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.
D. Any brachytherapy procedure approved in 10 CFR 35.400.
E. Medical use of sealed sources included in 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
F. In vitro studies.
G. through X. Research and development as described in 10 CFR 30.4; animal studies.
Y. Non-human use. For calibrations and checking of instruments.

CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at 119 Belmont Street, Worcester, Massachusetts.

11. The Radiation Safety Officer for this license is Norio Higano, M.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Norio Higano, M.D.	35.100; 35.200; 35.300; 35.400; 35.500 In vitro studies. Items 6.G. through 6.X. for research and development; animal studies Item 6.Y. for instrument calibration
Peter B. Schneider, M.D.	35.100; 35.200; 35.300; 35.500 In vitro studies Items 6.G. through 6.X. for research and development; animal studies Item 6.Y. for instrument calibration
Rob[illegible] S. Harper, M.D.	In vitro studies
Won K. Tak, M.D.	35.400

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02452-01
Docket or Reference number: 030-01847
Amendment No. 39

(12. continued) CONDITIONS

Authorized User(s)	Material and Use
James J. Hoogasian	Items 6.G. through 6.X. for research and development; animal studies
Anita M. Natale	Items 6.G. through 6.X. for research and development; animal studies
Catherine E. Waud, M.D.	35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.

15. The licensee shall not acquire licensed material in a sealed source or device unless the source or device has been registered with the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an Agreement State.

16. Licensed material specified in Items 6.G through 6.Y shall not be used in or on human beings.

17. A. Sealed sources and detector cells containing licensed material shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as are specified by the certificate of registration referred to in 10 CFR 32.210, not to exceed three years.

B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.

C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

(17. continued) CONDITIONS

E. Sealed sources and detector cells need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source or detector cell shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within five days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety Branch, 475 Allendale Road, King of Prussia, Pennsylvania 19406. The report shall specify the source or detector cell involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

G. The licensee is authorized to collect leak test samples for analysis by the licensee. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

18. The licensee shall conduct a physical inventory every six months to account for all sealed sources and devices containing licensed material received and possessed under the license. Records of inventories shall be maintained for five years from the date of each inventory, and shall include the quantities and kinds of byproduct material, manufacturer name and model numbers, location of sources and/or devices, and the date of the inventory.

19. Patients containing cobalt 60, cesium 137 or iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for 5 years from the time the implants are removed.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02452-01
Docket or Reference number: 030-01847
Amendment No. 39

(continued) CONDITIONS

20. Patients containing iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

21. The licensee may transport licensed material in accordance with the provisions of 10 CFR 71, "Packaging and Transportation of Radioactive Material."

22. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash, provided:

    A. Waste to be disposed of in this manner shall be held for decay a minimum of ten half-lives.

    B. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

    C. A record of each such disposal shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

    D. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

23. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

24. Experimental animals, or the products from experimental animals, that have been administered licensed materials shall not be used for human consumption.

25. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated November 12, 1990
    B. Letter dated October 11, 1991
    C. Letter dated March 3, 1994

For the U.S. Nuclear Regulatory Commission

Date SEP 26 1994

By John V. Stanbaugh
Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

Jims Copy

NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 10

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. The Medical Center of Centeral Massachusetts - Memorial 2. 119 Belmont Street Worcester, Massachusetts 01605-2982	In accordance with letter dated November 16, 1989, 3. License number 20-02452-03 is amended in its entirety to read as follows:
	4. Expiration date July 31, 1996
	5. Docket or Reference No 030-00234

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Cobalt 60	A. Teletherapy sealed sources (AECL Model C-146 or C-151)	A. 7,500 curies per source Not to exceed 15,000 curies total)

9. Authorized use

A. One source for medical use described in 10 CFR 35.600, in an AECL Theratron 780C teletherapy unit. One source in its shipping container or as necessary for replacement of the source in the teletherapy unit.

CONDITIONS

10. Location of use: Medical Center of Central Massachusetts - Memorial, Radiation Oncology Department, ~~South Wing~~, ~~Ground Floor, 119 Belmont Street, Worcester,~~ Massachusetts. Cancer Center Second floor ? ~~55 Lordell St~~

11. A. Radiation Safety Officer: Norio Higano, M.D.

12. A. Authorized User(s):

Won K. Tak, M.D. Medical Use described in 10 CFR 35.600

B. Teletherapy Physicist: Mabini M. Castro, Ph.D.

13. Pursuant to 10 CFR 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of uranium contained as shielding material.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
20-02452-03

Docket or Reference number
030-00234

Amendment No. 10

(Continued) CONDITIONS

14. The licensee is exempted from decommissioning financial assurance requirements for possession of licensed material in sealed sources in quantities greater than the limits in 10 CFR 30.35(d) for the purpose of source changes only. This exemption is granted for no more than 30 days for any one source change.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated December 15, 1987
B. Letter dated November 26, 1989
C. Letter dated June 21, 1991

For the U.S. Nuclear Regulatory Commission

Original Signed By:
Jenny Johansen

Date JUL 3 0 1991

By _____

Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

THE MEDICAL CENTER OF CENTRAL MASSACHUSETTS

119 Belmont Street
Worcester, MA
01605-2982

(508) 793-6611
FAX (508) 793-6324

October 4, 1995

U. S. Nuclear Regulatory Commission
Region I
Nuclear Materials Section B
475 Allendale Road
King of Prussia, PA 19406

RE: License No. 20-02452-01, 20-02452-03, and 20-15761-01

Dear Sirs:

It has come to my attention that it is not necessary at this time to file an amendment with the Nuclear Regulatory Commission regarding license numbers 20-02452-01, 20-02452-03, and 20-15761-01. Therefore, I would like to rescind my previous letter dated September 29, 1995.

Due to recent structural changes of the Memorial Nuclear Medicine Department, the daily operation of the above licenses will be assumed by the physicians currently operating under license number 20-15761-01 of the Hahnemann campus.

Amendments will be filed with the Nuclear Regulatory Commission as soon as possible requesting the necessary changes to the Memorial license.

Sincerely,

Harry G. Dorman, III
President, Hospital Division

/mjs

122357/122358

OFFICIAL RECORD COPY ML 10

OCT 10 1995

030-00234

THE MEDICAL CENTER OF CENTRAL MASSACHUSETTS

119 Belmont Street
Worcester, MA
01605-2982

(508) 793-6611
FAX (508) 793-6324

September 29, 1995

U.S. Nuclear Regulatory Commission
Region I
Nuclear Materials Section B
475 Allendale Rd
King of Prussia, PA 19406

Re: License No. 20-02452-01, 20-02452-03, and 20-15761-01

Dear Sirs,

This emergency amendment request is to change the Radiation Safety Officer (RSO) and authorized users from our present licensing at the Nuclear Regulatory Commission (NRC).

On license #20-02452-01 and 20-02452-03 we would like to delete the RSO Norio Higano, M.D. Also on license #20-02452-01 we would like to delete the Authorized User James J. Hoogasian.

On license #20-02452-01 and 20-02452-03 we would like to add the RSO Richard Danford M.D. from license #20-15761-01. Also on license #20-02452-01 we would like to add Authorized Users Edward Hurwitz, M.D. and Richard Danford M.D. from license #20-15761-01 for 10CFR35.100, 35.200, 35.300 and James W. Adams for items 6.G. through 6.X. for research and development; animal studies and 6.Y. for instrument calibration. NRC form 313M suppl A is attached to verify Mr. Adams' training and experience.

A copy of the licenses are attached. We also will commit to $430.00 in amendment fees at a future date. Kindly contact us when the emergency amendment is complete and fax a copy to #(508) 793-5576 by Saturday 6:00 p.m. September 30, 1995. If you need additional information please call Mr. Adams at (508) 793-6284.

Sincerely,

Harry G. Dorman

Harry G. Dorman, III - President, Hospital Division

NRC FORM 313M SUPPLEMENT A (9-81) U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE
JAMES W. ADAMS	

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING: LECTURE/LABORATORY COURSES (Hours) C	TYPE AND LENGTH OF TRAINING: SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	U. MASS MEDICAL CENTER/ WORCESTER STATE COLLEGE 486 CHANDLER ST WORCESTER, MASS 9/84-5/85	42	28
b. RADIATION PROTECTION	U. MASS MEDICAL CENTER/ WORCESTER STATE COLLEGE 486 CHANDLER ST WORCESTER, MASS 9/84-5/85	42	14
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	U. MASS MEDICAL CENTER/ WORCESTER STATE COLLEGE 486 CHANDLER ST WORCESTER, MASS 9/84-5/85	84	14
d. RADIATION BIOLOGY	U. MASS MEDICAL CENTER/ WORCESTER STATE COLLEGE 486 CHANDLER ST WORCESTER, MASS 9-12/83	42	
e. RADIOPHARMACEUTICAL CHEMISTRY	U. MASS MEDICAL CENTER/ WORCESTER STATE COLLEGE 486 CHANDLER ST WORCESTER, MASS 9-12/86	28	14

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
I 131	200 mCi	U. MASS MEDICAL CENTER & THE MEDICAL CENTER OF CENTRAL MASS		Treatment prep Iodinations, research
I123	300 microCi	U. MASS MEDICAL CENTER & THE MEDICAL CENTER OF CENTRAL MASS		Diagnostic
Tc99 m	35 mCi	U. MASS MEDICAL CENTER &THE MEDICAL CENTER OF CENTRAL MASS		Diagnostic

CONTINUED ON NEXT PAGE

NRC FORM 313M SUPPLEMENT A (9-81) U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE
JAMES W. ADAMS CONTINUED	

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
H3	5 mCi	THE MEDICAL CENTER OF CENTRAL MASS		RESEARCH
C14	100 uCi	THE MEDICAL CENTER OF CENTRAL MASS		RESEARCH & DIAGNOSTIC
P32	5 mCi	THE MEDICAL CENTER OF CENTRAL MASS		RESEARCH & DIAGNOSTIC
Cr51	300 uCi	THE MEDICAL CENTER OF CENTRAL MASS		RESEARCH & DIAGNOSTIC
Co58	1 uCi.	THE MEDICAL CENTER OF CENTRAL MASS		RESEARCH & DIAGNOSTIC
I125	1 mCi	THE MEDICAL CENTER OF CENTRAL MASS		RESEARCH & DIAGNOSTIC
Cs137	160 mCi	THE MEDICAL CENTER OF CENTRAL MASS		INSTRUMENT CALIBRATION

NRC FORM 313M S. (SUPPLEMENT A)

THE MEDICAL CENTER OF CENTRAL MASSACHUSETTS

119 Belmont Street
Worcester, MA
01605-2982

(508) 793-8811
FAX (508) 793-6324

4/28/95

Dear Sir;

Mr. James W. Adams has asked me for a letter describing his experience as a Radiation Safety Specialist at the Medical Center of Central Massachusetts under my supervision and I am glad to do so. James has worked under my supervision for 5 years and is very capable of implementing the requirements of license #20-02452-01 and #20-02452-03. This letter corresponds with 10CFR35.900b.2 and would grandfather Mr. Adams to be a Radiation Safety Officer in the future if he so chooses.

Sincerely,

N. Higano, M.D.

Norio Higano, M.D.
Radiation Safety Officer

NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 39

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. The Medical Center of Central Massachusetts - Memorial 2. 119 Belmont Street Worcester, Massachusetts 01605-2982	In accordance with the letter dated March 3, 1994, 3. License number 20-02452-01 is amended in its entirety to read as follows: 4. Expiration date December 31, 1996 5. Docket or Reference No 030-01847

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material included in 10 CFR 35.100	A. Any radiopharmaceutical included in 10 CFR 35.100 unsealed uptake, dilution, excretion studies	A. As needed
B. Any byproduct material included in 10 CFR 35.200	B. Any radiopharmaceutical included in 10 CFR 35.200 unsealed for imaging and localization studies	B. As needed
C. Any byproduct material included in 10 CFR 35.300	C. Any radiopharmaceutical included in 10 CFR 35.300 unsealed for Rx therapy	C. As needed
D. Any byproduct material included in 10 CFR 35.400	D. Any radiopharmaceutical included in 10 CFR 35.400 Sources for brachytherapy Cs^{137} Co^{60} Au^{198} Ir^{192} Sr^{90} I^{125} Pd^{103} Tlc	D. 2000 millicuries
E. Any byproduct material included in 10 CFR 35.500	E. Any diagnostic source included in 10 CFR 35.500 Sealed for diagnosis	E. As needed
F. Any byproduct material included in 10 CFR 31.11	F. Prepackaged Kits 60 or Lic # 20-02452-01 Sealed Source in Teletherapy	F. As needed
G. Hydrogen 3	G. Any	G. 100 millicuries
H. Carbon 14	H. Any	H. 50 millicuries
I. Phosphorus 32	I. Any	I. 40 millicuries
J. Chromium 51	J. Any	J. 10 millicuries
K. Iron 59	K. Any	K. 10 millicuries
L. Cobalt 58	L. Any	L. 10 millicuries
M. Cobalt 60	M. Any	M. 0.4 millicurie
N. Selenium 75	N. Any	N. 10 millicuries
O. Strontium 85	O. Any	O. 10 millicuries
P. Yttrium 90	P. Any	P. 400 millicuries
Q. Technetium 99m	Q. Any	Q. 100 millicuries
R. Indium 113m	R. Any	R. 100 millicuries
S. Iodine 125	S. Any	S. 15 millicuries
T. Iodine 131	T. Any	T. 15 millicuries
U. Ytterbium 169	U. Any	U. 10 millicuries

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
20-02452-01

Docket or Reference number
030-01847

Amendment No. 39

(Items 6., 7., & 8. continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
V. Gold 198	V. Any	V. 10 millicuries
W. Mercury 197	W. Any	W. 10 millicuries
X. Mercury 203	X. Any	X. 10 millicuries
Y. Cesium 137	Y. Sealed sources	Y. 200 millicuries

9. Authorized use

A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
B. Any imaging and localization procedure approved in 10 CFR 35.200.
C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.
D. Any brachytherapy procedure approved in 10 CFR 35.400.
E. Medical use of sealed sources included in 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
F. In vitro studies.
G. through X. Research and development as described in 10 CFR 30.4; animal studies.
Y. Non-human use. For calibrations and checking of instruments.

CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at 119 Belmont Street, Worcester, Massachusetts.

11. The Radiation Safety Officer for this license is Norio Higano, M.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Norio Higano, M.D.	35.100; 35.200; 35.300; 35.400; 35.500 In vitro studies. Items 6.G. through 6.X. for research and development; animal studies Item 6.Y. for instrument calibration
Peter B. Schneider, M.D.	35.100; 35.200; 35.300; 35.500 In vitro studies Items 6.G. through 6.X. for research and development; animal studies Item 6.Y. for instrument calibration
Robert S. Harper, M.D.	In vitro studies
Won K. Tak, M.D.	35.400

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02452-01
Docket or Reference number: 030-01847
Amendment No. 39

(12. continued) CONDITIONS

Authorized User(s)	Material and Use
James J. Hoogasian	Items 6.G. through 6.X. for research and development; animal studies
Anita M. Natale	Items 6.G. through 6.X. for research and development; animal studies
Catherine E. Waud, M.D.	35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.

15. The licensee shall not acquire licensed material in a sealed source or device unless the source or device has been registered with the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an Agreement State.

16. Licensed material specified in Items 6.G through 6.Y shall not be used in or on human beings.

17. A. Sealed sources and detector cells containing licensed material shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as are specified by the certificate of registration referred to in 10 CFR 32.210, not to exceed three years.

B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.

C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02452-01

Docket or Reference number: 030-01847

Amendment No. 39

(17. continued) CONDITIONS

E. Sealed sources and detector cells need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source or detector cell shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within five days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety Branch, 475 Allendale Road, King of Prussia, Pennsylvania 19406. The report shall specify the source or detector cell involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

G. The licensee is authorized to collect leak test samples for analysis by the licensee. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

18. The licensee shall conduct a physical inventory every six months to account for all sealed sources and devices containing licensed material received and possessed under the license. Records of inventories shall be maintained for five years from the date of each inventory, and shall include the quantities and kinds of byproduct material, manufacturer name and model numbers, location of sources and/or devices, and the date of the inventory.

19. Patients containing cobalt 60, cesium 137 or iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for 5 years from the time the implants are removed.

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02452-01
Docket or Reference number: 030-01847
Amendment No. 39

(continued) CONDITIONS

20. Patients containing iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

21. The licensee may transport licensed material in accordance with the provisions of 10 CFR 71, "Packaging and Transportation of Radioactive Material."

22. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash, provided:

    A. Waste to be disposed of in this manner shall be held for decay a minimum of ten half-lives.

    B. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

    C. A record of each such disposal shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

    D. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

23. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

24. Experimental animals, or the products from experimental animals, that have been administered licensed materials shall not be used for human consumption.

25. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated November 12, 1990
    B. Letter dated October 11, 1991
    C. Letter dated March 3, 1994

For the U.S. Nuclear Regulatory Commission

Original Signed By:
JoAnn V. Stambaugh

Date SEP 26 1994

By

Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

NRC FORM 374 (10-89) U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 2 PAGES

MATERIALS LICENSE

Amendment No. 10

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. The Medical Center of Centeral Massachusetts - Memorial 2. 119 Belmont Street Worcester, Massachusetts 01605-2982	In accordance with letter dated November 16, 1989, 3. License number 20-02452-03 is amended in its entirety to read as follows: 4. Expiration date July 31, 1996 5. Docket or Reference No 030-00234

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Cobalt 60	A. Teletherapy sealed sources (AECL Model C-146 or C-151)	A. 7,500 curies per source Not to exceed 15,000 curies total)

9. Authorized use

A. One source for medical use described in 10 CFR 35.600, in an AECL Theratron 780C teletherapy unit. One source in its shipping container or as necessary for replacement of the source in the teletherapy unit.

CONDITIONS

10. Location of use: Medical Center of Central Massachusetts - Memorial, Radiation Oncology Department, ~~South Wing, Ground Floor, 119 Belmont Street,~~ Worcester, Massachusetts. Cancer Center Second floor ? ~~55 Lincoln St.~~

11. A. Radiation Safety Officer: Norio Higano, M.D.

12. A. Authorized User(s):

Won K. Tak, M.D. Medical Use described in 10 CFR 35.600

B. Teletherapy Physicist: Mabini M. Castro, Ph.D.

13. Pursuant to 10 CFR 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of uranium contained as shielding material.

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

PAGE 2 OF 2 PAGES

License number 20-02452-03

Docket or Reference number 030-00234

Amendment No. 10

(Continued) CONDITIONS

14. The licensee is exempted from decommissioning financial assurance requirements for possession of licensed material in sealed sources in quantities greater than the limits in 10 CFR 30.35(d) for the purpose of source changes only. This exemption is granted for no more than 30 days for any one source change.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated December 15, 1987
B. Letter dated November 26, 1989
C. Letter dated June 21, 1991

For the U.S. Nuclear Regulatory Commission

Original Signed By:
Jenny Johansen

By _____
Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

Date JUL 3 0 1991

OFFICIAL RECORD COPY ML 10

122358

NRC FORM 577 (10-94)

U.S. NUCLEAR REGULATORY COMMISSION

LICENSE FEE REQUIREMENTS

LICENSE FEE AND DEBT COLLECTION BRANCH
DIVISION OF ACCOUNTING AND FINANCE
OFFICE OF THE CONTROLLER
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001
ATTN BRENDA BROWN

MEDICAL CENTER OF CENTRAL MASS.
ATTN: HARRY G. DORMAN, III
PRESIDENT, HOSPITAL DIVISION
119 BELMONT STREET
WORCESTER, MA 01605-2982

TYPE OF ACTION

- [ ] NEW LICENSE
- [ ] RENEWAL OF LICENSE
- [X] AMENDMENT TO LICENSE

REQUESTED DATE: LETTER DATED 9/29/95

LICENSE NUMBER: 20-02452-03

CONTROL NUMBER: 12235P

I. APPLICATION FEE DUE

Your request for a licensing action is subject to the fee(s) in the category(ies) noted below in accordance with Section 170.31 of the enclosed Federal Register notice. Payment of the fee is required prior to the issuance of the license, renewal, or amendment.

FEE CATEGORY	APPLICATION	RENEWAL	AMENDMENT
7A	$	$	$ 450
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$

FEE(s) DUE $ 450
PAYMENT RECEIVED $ -0-
AMOUNT DUE $ 450

- [X] Your request was received without the prescribed application fee.
- [ ] We received your Check No. _____ in the amount of $ _____. Payment of the additional fee noted above is required.
- [ ] Your request will increase the scope of your license program. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(d)(2).
- [ ] Your license expired prior to the receipt of your application for renewal. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(a).

MAKE PAYMENT OF THE FEE(S) TO THE U.S. NUCLEAR REGULATORY COMMISSION AND MAIL THE PAYMENT TO THE ADDRESS LISTED AT THE TOP OF THIS FORM. IF WE DO NOT RECEIVE A REPLY FROM YOU WITHIN 30 CALENDAR DAYS FROM THE DATE LISTED BELOW, WE SHALL ASSUME THAT YOU DO NOT WISH TO PURSUE YOUR APPLICATION AND WILL VOID THIS ACTION.

II. FEE NOT REQUIRED

- [ ] Enclosed is Check No. _____ which accompanied your request. The fee is not required because:
  - [ ] We received your Check No. _____ in payment of the fee.
  - [ ] The Licensing staff has informed us that your request is to be considered as a continuation of your request dated _____, Control No. _____
  - [ ] Your request was combined, prior to review, with your _____ request, Control No. _____

III. CHECK RETURNED

- [ ] Enclosed is Check No. _____ which was returned to us by the bank for:
  - [ ] INSUFFICIENT FUNDS
  - [ ] ACCOUNT CLOSED
  - [ ] OTHER

MAIL THE REPLACEMENT CHECK TO THE ADDRESS LISTED AT THE TOP OF THIS FORM AND REFERENCE THE ABOVE CONTROL NUMBER.

IV. LICENSE ISSUED WITHOUT THE REQUIRED FEE

- [ ] License No. _____, Amendment No. ____, issued on _____ was issued without the required fee being collected. The fee required is noted in Section I of this form.
- [ ] The scope of your licensed program was increased. Therefore, your request is subject to the application fee(s) noted in Section 1 of this form. Refer to Section 170.31 and Footnote 1(d)(2).
- [ ] Because of the urgency of your request, the license was issued without remittance of the prescribed fee noted in Section 1 of this form.

SIGNATURE - LICENSE FEE ANALYST	LFDCB	LFDCB
Brenda Brown	BB	
	11/30/95	/ /

DISTRIBUTION
OC/DAF/RF
LFDCB R/F
Pending Fee File
Region I

DATE: 11/30/95

NRC FORM 577 (10-94)

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02300
STATUS CODE: 0
FEE CATEGORY: 7A 2B
EXP. DATE: 1996073.
FEE COMMENTS: CODE 23
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: MEDICAL CTR. OF CENTRAL MASS. (THE)
RECEIVED DATE: 950929
DOCKET NO: 3000234
CONTROL NO.: 122358
LICENSE NO.: 20-02452-03
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: ---------
CHECK NO.: ---------

3. COMMENTS

SIGNED Brown, Rebecca J.
DATE 10/03/95

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED ✓)

1. FEE CATEGORY AND AMOUNT: (7A) 2B $450

2. CORRECT FEE PAID. ✓ APPLICATION MAY BE PROCESSED FOR:
AMENDMENT ---
RENEWAL ---
LICENSE ---

3. OTHER ---

SIGNED Brenda Byrne
DATE 3/11/96

I (YC)
Log Nov 2
Remitter
Check No. 345879
Amount $450
Fee Category (7A) 2B
Type of Fee Amd
Date Check Rec'd 3/11/96
Date Completed
By: Brenda Byrne